The Latest Breaking News from Pfizer

Here's a roundup of top developments in the biotech space over the last 24 hours:

Pfizer will acquire migraine drugmaker Biohaven Pharmaceuticals for nearly $12 billion in a deal that sent BHVN stock rocketing.

Pfizer Inc (NYSE:PFE) will acquire Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) for $148.50 per share, equivalent to $11.6 billion.  Pfizer will also make payments at closing to settle Biohaven's third-party debt and for the redemption of all outstanding shares of Biohaven's redeemable preferred stock.  The deal includes the acquisition of rimegepant (NURTEC ODT), a dual-acting…

Pfizer is spending $11.6 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own

It is "over and above" the level of protection that people who have had their third jab receive, according to the latest research.

Chance of stillbirth reduced by 15%, researchers find, after examining studies and trials that enrolled 117,552 women

Pfizer is trying to keep its exclusive rights to the billion dollar arthritis drug Enbrel in a lawsuit before the Federal Court.

Levels of antibodies waned in period between third jabs and fourth boosters

A ‘hint’ that some people might have already reached ‘ceiling’ in terms of protection they could acquire from fourth jab

UK-based team finds antibodies peaked higher after fourth jab given after gap of more than six months than after third

Academics have been monitoring the levels of protection post-vaccination.